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ABSTRACT: Two groups of novel hydroxypyridinone derivatives 6(a-e) and 12(a-c), 
were designed as potential tyrosinase inhibitors, and synthesized using kojic acid as a 
starting material. The tyrosinase inhibitory activity of these two groups was 
demonstrated to be potent, especially compounds 6e and 12a, whose IC50 values for 
monophenolase activity were 1.95 µM and 2.79 µM, respectively. Both of these 
values are lower than that of kojic acid (IC50 = 12.50 µM). Compounds 6e and 12a 
were investigated for the inhibitory effect on diphenolase activity. The results showed 
that the inhibitory mechanism of these two compounds was reversible and that the 
inhibitory type was a competitive-uncompetitive mixed-type. The values of IC50 of 6e 
and 12a on the diphenolase activity of tyrosinase were determined to be 8.97 µM and 
26.20 µM, respectively. The inhibitory constants (KI and KIS) of 6e were determined 
as 17.17 µM and 22.09 µM, respectively; and the KI and KIS values of 12a were 34.41 
µM and 79.02 µM, respectively. Compound 6e showed a greater ability to reduce 
copper and a stronger copper chelating ability than kojic acid.  
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Tyrosinase (EC 1.14.18.1), a multifunctional copper-containing enzyme from the 
oxidase superfamily, is widely distributed in mammals, plants, microorganisms, and 
insects.
1 
The active site of tyrosinase is well conserved among the different species. 
Six histidine residues, which are provided by a fourhelical bundle, coordinate the two 
copper ions, which serve as the major cofactors in the active site.
2,3
 Tyrosinase can 
catalyze the first and rate-limiting step of melanin formation, namely the 
hydroxylation of L-tyrosine to L-3-(3,4-dihydroxyphenyl)-alanine (L-DOPA) 
(monophenolase activity) and also the subsequent oxidation of DOPA to dopaquinone 
(diphenolase activity).
4 
Dopaquinone is highly reactive and can polymerize 
spontaneously to form melanin in a series of reaction pathways.
5
 Therefore, tyrosinase 
plays an important role in the pigmentation of skin,
6,7
 the browning of fruits and 
vegetables,
8,9 
wound healing,
10
 and cuticle formation in insects.
11,12 
Tyrosinase is also 
involved in neuromelanin formation in the brain and neurodegeneration associated 
with Parkinson’s disease.13,14 Thus, tyrosinase inhibitors have attracted increasing 
attention. In principle, tyrosinase inhibitors have potential applications in the 
agricultural, cosmetic and pharmaceutical industry.  
Numerous effects have been made to develop potent and safe tyrosinase inhibitors 
from natural materials and synthetic methods.
15-19
 However, only a few are 
sufficiently potent for practical use and comply with the general safety regulations. 
Thus, there is a demand for novel tyrosinase inhibitors with superior activity together 
with reduced side effects. Kojic acid (1), a metabolic product of many species of 
Aspergillus and Penicillium moulds, has been used as an ingredient in cosmetics and 
as an anti-browning agent in foods that rapidly change colour by virtue of its 
appreciable anti-tyrosinase and antioxidant activities.
20-23
 Thus, modification of kojic 
acid provides a potential route for superior tyrosinase inhibitors.
24-27
 Kojic acid has 
been demonstrated to inhibit tyrosinase by chelating the copper ion normally present 
in the active site of tyrosinase. Using the principle of bioisosterism, we have changed 
the “O” at position-1 in pyranone ring to “NH”, synthesizing a range of 
hydroxypyridinone-amino acid and hydroxypyridinone-dipeptide conjugates. Their 
tyrosinase inhibitory activity and mechanism of inhibition have been investigated. 
  
 
Hydroxypyridinone-L-amino acid conjugates (6) were synthesized starting from 
kojic acid (1) (Scheme 1). Benzylation of 5-hydroxy group in kojic acid was achieved 
by the reaction of kojic acid and benzyl chloride under basic condition to provide 2 in 
good yield (80%). Condensation of 2 with ammonia generated 3 (74%), which was 
then subjected to hydrogenation to remove benzyl group, providing compound 4 
(82%). Coupling of 4 with Cbz-L-amino acid (5) via ester bond was carried out in the 
presence of EDC and DMAP in DMF at room temperature, yielding product 6.
28
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Scheme 1.Reagents and conditions: (a) BnCl, MeOH/H2O, 70
o
C, 6h, 80 % yield; (b) 
aqueous NH3 (37%), EtOH, reflux, overnight, 74 % yield; (c) MeOH/H2O, H2(30psi), 
5% Pd/C, rt, 8h, 82 % yield; (d) Cbz-L-amino acid (5), EDC, DMAP, DMF, ice-bath, 
2h; then rt overnight. 
 
The synthetic route of hydroxypyridinone-dipeptide conjugates (12) is presented 
in Scheme 2. Compound 3 was treated with thionyl chloride, followed by the reaction 
with aqueous ammonia, providing amino group-containing compound 7. N-benzyl 
oxygen carbonyl-L-phenylalanine (5a) reacted with methyl ester of L-amino acid (8) 
in the presence of HCTU, generating compounds 9, which were then hydrolyzed to 
produce compounds 10. The coupling of 10 with 7 was achieved in the presence of 
HCTU, yielding compounds 11, which were subjected to hydrogenation in the 
presence of Pd/C catalyst, providing hydroxypyridinone-dipeptide conjugates 12.
29 
  
All the compounds have been fully characterized by 
1
H NMR, 
13
C NMR and HRMS. 
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Scheme 2.Reagents and conditions: (a) i) SOCl2, rt, 18h; ii) methanol, aqueous 
ammonia (37%), rt 2h, then 40
o
C 8h, 69.5% yield; (b) DMF, HCTU, DIPEA, ice-bath 
4-6h, over 93% yield; (c) MeOH/H2O, LiOH, ice-bath 6-8h, hydrochloric acid; (d) 
DMF, HCTU, DIPEA, ice-bath 2h, then rt overnight; (e) H2 (30psi), Pd/C (5%), BnCl, 
EtOAc/MeOH (1:1), rt 8-10h. 
 
Inhibitory activity of hydroxypyridinone derivatives 6 and 12 on monophenolase 
activity of mushroom tyrosinase was investigated using L-tyrosine as a substrate.
30
 
The inhibitory effects on mushroom tyrosinase increased with the increase of 
concentrations of hydroxypyridinone derivatives (Figure 1). As shown in Figure 1A, 
the inhibitory activity of compounds 6 follows the order: 6e > 6a > 6d > 6c > 6b. The 
IC50 values of compounds 6a-6e were calculated to be 11.76, 28.71, 15.62, 12.48 and 
1.95 μM respectively. Among these five hydroxypyridinone-amino acid derivatives, 
compound 6e was found to exhibit the strongest inhibition against monophenolase 
activity of tyrosinase, being 6.4-fold more active than kojic acid (IC50 = 12.50 μM). 
Based on the data presented in Figure 1B, the IC50 values of compounds 12a-12c were 
calculated to be 2.79, 6.93 and 14.26 μM, respectively. Compounds 12a and 12b are 
  
4.5 and 1.8-fold more active than kojic acid against monophenolase activity of 
tyrosinase. Compound 12c was found to have a lower inhibitory activity than kojic 
acid. Both copper-binding affinity and lipophilicity are important factors affecting the 
anti-tyrosinase activity. The copper-binding affinities of the hydroxypyridinone 
derivative prepared in the present study are anticipated to be similar due to the same 
chelating moieties and similar electronic effect of substituted group at position-6 in 
pyridine ring. For compounds 12, the inhibitory effect decreased with the decrease of 
hydrophobicity (Clog P for 12a, 12b and 12c are calculated to be 0.12, -0.04 and 
-0.57),
31 
which is in good agreement with previously published results.
4,14
 However, 
for compounds 6, the inhibitory effects do not follow the order of hydrophobicity 
probably due to their high hydrophobicity (ClogP: 6a 2.86; 6b 4.17; 6c 4.14; 6d 3.64; 
6e 4.32). With such a high lipophilicity, these compounds are anticipated to readily 
enter the hydrophobic pocket of tyrosinase. In such cases, it is reasonably reckoned 
that the inhibitory activity mainly depends on the complimentary fit between the 
compound and active site of enzyme, which is affected by the substituting group and 
position on the pyridinone ring. In our previous study, it was found that 
hydroxypyridinone derivatives with a substitute at position-2 in pyridine ring had 
hardly anti-tyrosinase activity, although they have superior copper-binding affinity 
and higher lipophilicity than kojic acid.  
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Figure 1.Inhibition on monophenolase activity of tyrosinase. (A) compounds 6; (B) 
compounds 12. 
 
Inhibitory effect of 6e and 12a on diphenolase activity of mushroom tyrosinase 
was investigated using L-Dopa as a substrate. The kinetic courses of the oxidation of 
L-Dopa by mushroom tyrosinase in the presence of different concentrations of 
compound 6e or 12a were investigated. As shown in Figure 2, the formation of 
o-quinone increased with time. The absorbance values reduced with increasing 
concentration of compound 6e and 12a, indicating an increase of inhibitory effect. 
Under the same conditions, the inhibitory effect of compound 6e was better than that 
of compound 12a. In the cases of both 6e and 12a, the increasing rate of o-quinone 
formation became slower with increasing reaction time, indicating that the inhibitory 
effect decreased. In addition, the reaction process catalyzed by the diphenolase 
activity of tyrosinase had no lag time. 
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Figure 2. Inhibition kinetics on diphenolase activity of tyrosinase. (A) 6e; (B) 12a. 
The concentrations of inhibitors (6e and 12a) for curves 1-6 were 0.00, 4.17, 8.33, 
16.67, 25.00 and 33.33µM, respectively. 
 
As indicated in Figure 3, the relative activity of enzyme decreased with 
increasing concentration of inhibitor, indicating that the activity of enzyme was 
inhibited in a dose dependent manner. The IC50 values of compounds 6e and 12a were 
calculated to be 8.97 and 26.20 μM, respectively. Thus, 6e is more effective than 12a 
in the inhibition on diphenolase activity of tyrosinase. 
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Figure 3. Inhibitory effect of 6e and 12a on the diphenolase activity of tyrosinase. 
 
The inhibitory mechanism of 6e and 12a on mushroom tyrosinase was 
investigated using L-DOPA as a substrate. For both compounds, investigation on the 
relationship between enzyme activity and its concentration in the presence of 
compound 6e and 12a indicated that the plots of the remaining enzyme activity versus 
  
the concentration of enzyme at different inhibitor concentrations gave a family of 
straight lines, which all passed through the origin (Figure 4). This result is similar to 
that reported by Chen et al.
32
 Increase of inhibitor concentration resulted in descent of 
the slope of the line, indicating that the presence of inhibitor resulted in the inhibition 
of enzyme activity.
33 
Thus, the inhibition of both compounds 6e and 12a on 
diphenolase activity of tyrosinase is reversible. 
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Figure 4. Determination of the inhibitory mechanism of 6e (A) and 12a (B) on 
mushroom tyrosinase. The concentrations of inhibitors for curves 1-6 were 0.00, 4.17, 
8.33, 16.67, 25.00 and 33.33 µM, respectively. 
 
The kinetic data of the inhibition of L-DOPA oxidation by 6e and 12a were 
expressed in Lineweaver-Burk double-reciprocal plots (Figure 5A-I, B-I).
33
 The plots 
of 1/v versus 1/[S] gave a group of straight lines with different slopes that intercept in 
the second quadrant, indicating that both compounds 6e and 12a can bind not only 
  
with free enzyme but also with the enzyme−substrate complex, namely, both 6e and 
12a were competitive−uncompetitive mixed type inhibitors. The equilibrium constant 
of inhibitor for binding with free enzyme (KI) was obtained from a plot of slope 
(Km/Vm) versus the concentration of the inhibitor (Figure 5A-II and B-II), and with 
enzyme−substrate complex (KIS) was obtained from a plot of the vertical intercept 
(1/Vm) versus the concentration of the inhibitor (Figure 5A-III and B-III). The KI and 
KIS values of 6e were determined to be 17.17 μM and 22.09 μM, respectively. The 
inhibitor constants (KI and KIS) of 12a were determined as 34.41 μM and 79.02 μM, 
respectively. In both cases, the KIS value is larger than the KI value, indicating that the 
affinity of the inhibitors for free enzyme is greater than that for the enzyme-substrate 
complex.  
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Figure 5. Lineweaver–Burk plots (A-I and B-I) of mushroom tyrosinase with 
L-DOPA as a substrate in the presence of 6e (A) and 12a (B). A-II and B-II represent 
the plot of slope versus the concentration of 6e and 12a for determining the inhibition 
constants KI. A-III and B-III represent the plot of intercept versus the concentration of 
6e and 12a for determining the inhibition constants KIS. 
 
In order to further investigate the inhibitory mechanism of hydroxypyridinone 
derivatives, copper reduction capacity
34
 and copper chelating ability
35
 of compound 
6e were determined. The capacity of the reducing cupric ion to cuprous ion by 6e at 
different concentrations is shown in Figure 6A. The increases in absorbance value at 
483nm indicate the formation of cuprous ion. The absorbance increased with 
increasing concentration of compound 6e up to 0.15 mM, thereafter the absorbance 
remained unchanged, indicating that all cupric ions were reduced to cuprous ion. In 
the case of kojic acid, the absorbance at 483nm increased with the increase of its 
concentration until 0.3 mM, indicating that compound 6e possesses a stronger copper 
reducing capability than kojic acid. It is well known that tyrosinase exists in three 
isoforms, namely, oxy-tyrosinase [Cu(II)Cu(II)O2], met-tyrosinase [Cu(II)Cu(II)], and 
deoxy-tyrosinase [Cu(I)Cu(I)].
36
 Met-tyrosinase is reduced by reductant to 
deoxy-tyrosinase, which is then oxidized by oxygen, forming oxy-tyrosinase capable 
of catalyzing mono- or diphenol oxidation.
37
 Copper in the active site of tyrosinase 
0 5 10 15 20 25 30 35
0.00
0.05
0.10
0.15
0.20
II
S
lo
p
e
[I] (M)
0 5 10 15 20 25 30 35
0.0
0.2
0.4
0.6 III
In
te
rc
ep
t
[I] (M)
-6 -4 -2 0 2 4 6 8 10 12
0.5
1.0
1.5
2.0
2.5
3.0
1
2
3
4
5
1
/
 (
µ
M
/m
in
)-
1
1/[S] (mM)
-1
I
B 
  
plays a key role in browning reaction. Reduction of cupric ion to cuprous ion at the 
active site of tyrosinase by compound 6e could convert tyrosinase into the deoxy form. 
Thus, it is suggested that compound 6e could inhibit the dopachrome formation by 
reducing met-tyrosinase to deoxy-tyrosinase.   
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Figure 6. Copper reducing capacity (A) and copper chelating ability (B) of compound 
6e and kojic acid. 
 
   As shown in Figure 6B, at low concentrations (<1mM), the copper chelating 
ability of compound 6e and kojic acid both increased with increasing concentration (P 
< 0.05), after which the increasing rate rapidly slowed down and then reached a 
maximum. For compound 6e, at pH 5.0 and 7.4, copper chelating abilities were 
determined to be 91.34±0.28% and 83.34±0.29% at 0.952 mM, and 97.52±0.31% and 
88.92±0.33% at 2.857mM, respectively; while for kojic acid, at pH 5.0 and 7.4, they 
were 82.64±0.25% and 74.35±0.27% at 0.952 mM, reaching a maximum of 
90.10±0.25% and 80.08±0.22% at 3.81mM, indicating superior copper chelating 
B 
  
ability of 6e to that of kojic acid. Tyrosinase contains a coupled binuclear copper 
center in its active site. The two cupric ions, bound with three histidine residues, are 
directly involved in the different catalytic activities. When compound 6e enters the 
active site of the tyrosinase, it could outcompete with the histidine residues for the 
binding of cupric ion, thereby resulting in a loss of activity. The copper chelating 
activity of 6e was in accordance with its tyrosinase inhibitory activity (Figure 1). 
Therefore, copper chelation of 6e is one of the important mechanisms for the 
inhibition of tyrosinase. 
 
In order to understand the interaction mode of inhibitor binding to tyrosinase, the 
molecular docking of compound 6e to Agaricus bisporus tyrosinase
38
 was carried out 
using Accelrys Discovery Studio 2.5 software. As shown in Figure 7, the 
hydroxypyridinone ring of compound 6e can insert into the bottom of active pocket in 
tyrosinase, the 3-hydroxy group and 4-carbonyl group coordinate with copper ion. 
Two benzyl groups stretch out with a T shape, forming a stable combined 
conformation via hydrophobic interaction with hydrophobic area in the active pocket 
of tyrosinase, indicating a good deal of complimentary fit between compound 6e and 
active site of tyrosinase. 
    
 
 
 
 
 
 
 
 
 
Figure 7. Structure for the interaction of compound 6e with tyrosinase. 
 
   In summary, a range of hydroxypyridinone derivatives were synthesized in the 
present study. Among them, 6e was found to exhibit the highest tyrosinase inhibitory 
activity. 6e exhibited reversible and mixed type inhibition on mushroom tyrosinase. 
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Chelating copper at the active site of tyrosinase is an important mechanism for the 
inhibition of tyrosinase. Thus it could find application in medicine, cosmetic and 
agriculture areas. 
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